Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GSK plc(GSK) Shareholders
07:15pm, Wednesday, 26'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
09:01am, Wednesday, 26'th Mar 2025
The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are adv
Investors in GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK
07:25am, Wednesday, 26'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
NEW YORK CITY, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK p
4 IDEAYA/GSK presentations of IDE275 (GSK959) and 4 additional presentations across IDE397/MAT2A, IDE161/PARG, PRMT5, and KAT6/7 programs at AACR 2025 IDE275 (GSK959) has demonstrated a potential best
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) a
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
GSK plc Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion
05:34pm, Tuesday, 25'th Mar 2025
Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses
Lost Money on GSK plc (GSK)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
04:15pm, Tuesday, 25'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
Investors Who Lost Money on GSK plc (GSK) Should Contact Levi & Korsinsky About Pending Class Action - GSK
03:30pm, Tuesday, 25'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
GSK plc Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - GSK
02:30pm, Tuesday, 25'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow th
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE:GSK) between Febr
US FDA approves GSK's urinary tract infection drug
12:00pm, Tuesday, 25'th Mar 2025
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker h
